Comment on “Development and Validation of a META-Algorithm to Identify the Indications of Use of Biological Drugs Approved for the Treatment of Immune-Mediated Inflammatory Diseases from Claims Databases: Insights from the VALORE Project”. [Response to Letter]

Autor: Spini A, L'Abbate L, Ingrasciotta Y, Pellegrini G, Carollo M, Ientile V, Leoni O, Zanforlini M, Ancona D, Stella P, Cavazzana A, Scapin A, Lopes S, Belleudi V, Trifirò G

Publikováno v: Clinical Epidemiology, Vol Volume 16, Pp 445-446 (2024)

Andrea Spini,1 Luca L’Abbate,2 Ylenia Ingrasciotta,1 Giorgia Pellegrini,1 Massimo Carollo,1 Valentina Ientile,2 Olivia Leoni,3 Martina Zanforlini,4 Domenica Ancona,5 Paolo Stella,5 Anna Cavazzana,6 Angela Scapin,6 Sara Lopes,7 Valeria Belleudi,7 Gi

Externí odkaz: https://doaj.org/article/d86ee0f573b041408caaec6be84a9694

Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project

Autor: Trifiro, G., Isgro, V., Ingrasciotta, Y., Ientile, V., L'Abbate, L., Foti, S. S., Belleudi, V., Poggi, F., Fontana, A., Moretti, U., Lora, R., Sabaini, A., Senesi, I., Sorrentino, C., Puzo, M. R., Padula, A., Fusco, M., Giordana, R., Solfrini, V., Puccini, A., Rossi, P., Del Zotto, S., Leoni, O., Zanforlini, M., Ancona, D., Bavaro, V., Garau, D., Ledda, S., Scondotto, S., Allotta, A., Tuccori, M., Gini, R., Bucaneve, G., Franchini, D., Cavazzana, A., Biasi, V., Spila Alegiani, S., Massari, M., Andretta, I., Tanaglia, M., Carriero, A., Sassano, S., De Sarro, G., Mirarchi, S., Palleria, C., Sarro, C., Balestrieri, M., Rostan, S., Capuano, A., Bernardi, F. F., Trama, U., Russo, A., Fumo, M. G., Addis, A., Musicco, F., Sapigni, E., Mazzetti, I., Podetti, D., Potenza, A. M., Nikitina, V., Ricciardelli, R., Mogheiseh, N., Croce, S., Pettinelli, A., Ejlli, L., Fortino, I., Ercolanoni, M., Mazzone, A., Nisic, A., Schiatti, S., Ludergnani, M., Mancini, M., Patregnani, L., Fabbietti, P., Antonicelli, E., Mangano, A., Campomori, A., Urru, S. A., Costa, G., Guarrera, G. M., Stella, P., Serra, E., Carta, P., Vannacci, A., Lucenteforte, E., Parrilli, M., Convertino, I., De Giorgi, M., Rocchi, R. E., Rossi, M., Scroccaro, G., Deambrosis, P., Grindelli, G., Ferroni, E.

Publikováno v: Biodrugs

Background Biological drugs have improved the management of immune-mediated inflammatory diseases (IMIDs) despite being associated with important safety issues such as immunogenicity, infections, and malignancies in real-world settings. Objective The

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d534e4e1a9136f694040e1438c81213
https://doi.org/10.1007/s40259-021-00498-3

The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?

Autor: Trifirò, G, Gini, R, Barone-Adesi, F, Beghi, E, Cantarutti, A, Capuano, A, Carnovale, C, Clavenna, A, Dellagiovanna, M, Ferrajolo, C, Franchi, M, Ingrasciotta, Y, Kirchmayer, U, Lapi, F, Leone, R, Leoni, O, Lucenteforte, E, Moretti, U, Mugelli, A, Naldi, L, Poluzzi, E, Rafaniello, C, Rea, F, Sultana, J, Tettamanti, M, Traversa, G20, Vannacci, A, Mantovani, L, Corrao, G, Trifirò, Gianluca

Publikováno v: Drug safety. 42(3)

Enormous progress has been made globally in the use of evidence derived from patients’ clinical information as they access their routine medical care. The value of real-world data lies in their complementary nature compared with data from randomise

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39bcebed595a67894f60e58ff90ecb55
https://pubmed.ncbi.nlm.nih.gov/30269245

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study

Autor: Ingrasciotta, Y., Belleudi, V., Trotta, F., Addis, A., Fontana, A., Chinellato, A., Ientile, V., Tari, D. U., Roberto, G., Pastorello, M., Scondotto, S., Cananzi, P., Traversa, G., Davoli, M., Rossi, M., Trifiro, G., Caputi, A. P., Bolcato, J., Pirolo, R., Gini, R., Genazzani, A. A., Uomo, I., Addario, S. W. P., Da Cas, R.

Publikováno v: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 34(1)

Switching between different erythropoiesis-stimulating agents (ESAs) during the first year of therapy is frequent (15–20%), much more so toward reference products than biosimilars. The objectives of this study were to investigate the frequency and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e0566529292829c830491b9d3b7e433
https://pubmed.ncbi.nlm.nih.gov/31595485